XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in Capital
Treasury Stock, At Cost
Notes Receivable From Stockholders
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balance at beginning of period at Jun. 30, 2022 $ 32 $ 393,157   $ (95) $ (2,687) $ (333,550) $ 56,857
Balance at beginning of period (in shares) at Jun. 30, 2022 31,930            
Interest on stockholders' notes       (1)     (1)
Issuance of common stock upon exercise of stock options   568         568
Issuance of common stock upon exercise of stock options (in shares) 165            
Repurchase of common stock     $ (1,101)       (1,101)
Repurchase of common stock, shares (145)   145        
Issuance of common stock in connection with employee stock purchase plan   540         540
Issuance of common stock in connection with employee stock purchase plan (in shares) 72            
Stock-based compensation   5,283         5,283
Foreign currency translation adjustments         186   186
Net income (loss)           (492) (492)
Balance at end of period at Mar. 31, 2023 $ 32 399,548 $ (1,101) (96) (2,501) (334,042) 61,840
Balance at end of period (in shares) at Mar. 31, 2023 32,022            
Balance at end of period (in shares) at Mar. 31, 2023     145        
Balance at beginning of period at Dec. 31, 2022 $ 32 397,998   (96) (2,893) (333,670) 61,371
Balance at beginning of period (in shares) at Dec. 31, 2022 32,131            
Issuance of common stock upon exercise of stock options   103         103
Issuance of common stock upon exercise of stock options (in shares) 36            
Repurchase of common stock     $ (1,101)       (1,101)
Repurchase of common stock, shares (145)   145        
Stock-based compensation   1,447         1,447
Foreign currency translation adjustments         392   392
Net income (loss)           (372) (372)
Balance at end of period at Mar. 31, 2023 $ 32 399,548 $ (1,101) (96) (2,501) (334,042) 61,840
Balance at end of period (in shares) at Mar. 31, 2023 32,022            
Balance at end of period (in shares) at Mar. 31, 2023     145        
Balance at beginning of period at Jun. 30, 2023 $ 32 401,087 $ (5,763) (97) (2,122) (331,441) $ 61,696
Balance at beginning of period (in shares) at Jun. 30, 2023 31,482   786        
Balance at beginning of period (in shares) at Jun. 30, 2023             786
Interest on stockholders' notes       (1)     $ (1)
Repayment on stockholder notes       77     77
Issuance of common stock upon exercise of stock options $ 1 573         574
Issuance of common stock upon exercise of stock options (in shares) 185            
Repurchase of common stock     $ (8,529)       (8,529)
Repurchase of common stock, shares (1,355)   1,355        
Issuance of common stock in connection with employee stock purchase plan   417         417
Issuance of common stock in connection with employee stock purchase plan (in shares) 70            
Stock-based compensation   3,513         3,513
Foreign currency translation adjustments         (160)   (160)
Net income (loss)           6,274 6,274
Balance at end of period at Mar. 31, 2024 $ 33 405,590 $ (14,292) (21) (2,282) (325,167) $ 63,861
Balance at end of period (in shares) at Mar. 31, 2024 30,382   2,141        
Balance at end of period (in shares) at Mar. 31, 2024     2,141       2,141
Balance at beginning of period at Dec. 31, 2023 $ 32 404,320 $ (8,778) (20) (2,101) (326,660) $ 66,793
Balance at beginning of period (in shares) at Dec. 31, 2023 31,202            
Balance at beginning of period (in shares) at Dec. 31, 2023     1,260        
Interest on stockholders' notes       (1)     (1)
Issuance of common stock upon exercise of stock options $ 1 160         161
Issuance of common stock upon exercise of stock options (in shares) 61            
Repurchase of common stock     $ (5,514)       (5,514)
Repurchase of common stock, shares (881)   881        
Stock-based compensation   1,110         1,110
Foreign currency translation adjustments         (181)   (181)
Net income (loss)           1,493 1,493
Balance at end of period at Mar. 31, 2024 $ 33 $ 405,590 $ (14,292) $ (21) $ (2,282) $ (325,167) $ 63,861
Balance at end of period (in shares) at Mar. 31, 2024 30,382   2,141        
Balance at end of period (in shares) at Mar. 31, 2024     2,141       2,141